Nonsurgical innovations in the treatment of nonmelanoma skin cancer

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 6, 2010, Pages 20-34

  Amini, Sadegh ^a   Viera, Martha H ^a   Valins, Whitney ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALPHA INTERFERON; ALPHA INTERMEDIN DERIVATIVE; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BETULIC ACID; CAPECITABINE; CELECOXIB; CUV 1647; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPAMINE; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETRETIN; FLUOROURACIL; GAMMA INTERFERON; GDC 0449; GEFITINIB; IMIQUIMOD; INDOMETACIN; INGENOL; INTERFERON; ISOTRETINOIN; MELANIN; PERILLYL ALCOHOL; PLACEBO; RESIQUIMOD; RETINOID; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CEREBELLUM MEDULLOBLASTOMA; CHEMOPROPHYLAXIS; CLEARANCE; CLINICAL TRIAL; CREAM; CRYOSURGERY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERECTILE DYSFUNCTION; ERYTHEMA; EYE TOXICITY; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; HYPOTENSION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; KERATINOCYTE; LEUKOPENIA; LIVER TOXICITY; LOCAL SKIN REACTION; LOW LEVEL LASER THERAPY; MEDULLOBLASTOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NODULAR BASAL CELL CARCINOMA; NONHUMAN; NONSURGICAL INVASIVE THERAPY; PHOTODYNAMIC THERAPY; PRIMARY PREVENTION; PROTECTIVE CLOTHING; PSORIASIS; RHABDOMYOLYSIS; SKIN CANCER; SKIN CRUSTING; SKIN DISEASE; SKIN FLAKING; SKIN NECROSIS; SKIN SCALING; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR BIOPSY; TUMOR VOLUME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 77954504982     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (245)

1. Skin cancer. National Cancer Institute. http://www. cancer.gov/cancertopics/types/skin. Accessed on: March 4, 2010.
2. McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol. 2009;30(2):121-133.
3. Seidler AM, Bramlette TB, Washington CV, et al. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg. 2009;35(11):1776-1187.
4. King SC, Chen S. Analyzing the cost of preventing nonmelanoma skin cancer. J Invest Dermatol. 2009;129(12): 2745-2746.
5. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462-469.
6. Ho T, Byrne PJ. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am. 2009;17(3):301-307.
7. Ulrich M, Stockfleth E, Roewert-Huber J, et al. Noninvasive diagnostic tools for nonmelanoma skin cancer. Br J Dermatol. 2007;157 Suppl 2:56-58.
8. Ahlgrimm-Siess V, Hofmann-Wellenhof R, Cao T, et al. Reflectance confocal microscopy in the daily practice. Semin Cutan Med Surg. 2009;28(3):180-189.
9. Berman B, Viera M, Amini S, Valins W. Immune response modulators in the treatment of skin cancer. In: Rigel et al, ed. Cancer of the Skin. 2nd Edition. Chapter 44. In press.
10. Ge NN, McGuire JF, Dyson S, Chark D. Nonmelanoma skin cancer of the head and neck II: surgical treatment and reconstruction. Am J Otolaryngol. 2009;30(3):181-192.
11. Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother. 2009;10(18):3015-3031.
12. Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2009;17(3):309-324.
13. Nash JF, Tanner PR, Matts PJ. Ultraviolet A radiation: testing and labeling for sunscreen products. Dermatol Clin. 2006;24(1):63-74.
14. Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight-induced immunosuppression in human beings. J Am Acad Dermatol. 2008;58(5 Suppl 2):S149-S154.
15. Tuchinda C, Lim HW, Osterwalder U, Rougier A. Novel emerging sunscreen technologies. Dermatol Clin. 2006;24(1):105-117.
16. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11): 949-956.
17. Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer. 1999;80(1-2):1-8.
18. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr. 2000;130(2S Suppl):479S-482S.
19. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16(11-12): 1084-1089.
20. Nicholson RC, Mader S, Nagpal S, et al. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. 1990;9(13):4443-4454.
21. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994;372(6501):107-111.
22. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 1999;20(10):1939-1944.
23. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998;19(5):723-729.
24. Müller-Decker K, Reinerth G, Krieg P, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer. 1999;82(5):648-656.
25. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25(4):231-240.
26. Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther. 2006;19(5):306-314.
27. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32(4):562-568.
28. Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer. 2000;36(10): 1292-1297.
29. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41(3):269-285.
30. Bollag W, Ott F. Retinoic acid: topical treatment of senile or actinic keratoses and basal cell carcinomas. Agents Actions. 1970;1(4):172-175.
31. Barranco VP, Olson RL, Everett MA. Response of actinic keratoses to topical vitamin A acid. Cutis. 1970;6:681-685.
32. Bollag W, Ott F. Vitamin A acid in benign and malignant epithelial tumours of the skin. Acta Derm Venereol Suppl (Stockh). 1975;74:163-166.
33. Kurka M, Orfanos CE, Pullmann H. Vitamin A acid for the topical management of epithelial neoplasms. Combination with 5-fluorouracil. Hautarzt. 1978;29(6):313-318.
34. Kleinsmith DA, Thomas L. Retinoic acid in the treatment of actinic keratoses. J Dermatol Surg Oncol. 1988;14:103.
35. Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24(3):448-451.
36. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol. 1994;30(3):447-451.
37. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994;330(18): 1272-1275.
38. Ibiebele TI, van der Pols JC, Hughes MC, et al. Dietary fat intake and risk of skin cancer: a prospective study in Australian adults. Int J Cancer. 2009;125(7):1678-1684.
39. Black HS, Lenger WA, Gerguis J, Thornby JI. Relation of antioxidants and level of dietary lipid to epidermal lipid peroxidation and ultraviolet carcinogenesis. Cancer Res. 1985;45(12 Pt 1):6254-6259.
40. Belanger JT. Perillyl alcohol: applications in oncology. Altern Med Rev. 1998;3(6):448-457.
41. Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr. 1999;129(3):775S-778S.
42. Barthelman M, Chen W, Gensler HL, et al. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res. 1998;58(4):711-716.
43. Chaudhary SC, Alam MS, Siddiqui MS, Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact. 2009;179(2-3):145-153.
44. Stratton SP, Saboda KL, Myrdal PB, et al. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer. 2008;60(3):325-330.
45. Stratton S. Phase 2a randomized, placebo-controlled, double-blind trial of topical perillyl alcohol in sun damaged skin. ClinicalTrials.gov Identifier: NCT00608634. http://clinicaltrials.gov/ct2/show/NCT00608634. Accessed on: March 4, 2010
46. Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther. 2008;8(6):829-838.
47. Yarosh D, Klein J, O'Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet. 2001;357(9260):926-929.
48. Yarosh DB. Enhanced DNA repair of cyclobutane pyrimidine dimers changes thebiological response to UV-B radiation. Mutat Res. 2002;509(1-2):221-226.
49. Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol. 2008;7(4):405-408.
50. Yarosh D et al. A randomized, double-blind, multi-center clinical study to test the safety and efficacy of T4N5 liposome lotion on patients with xeroderma pigmentosum in the protection against actinic keratosis. ClinicalTrials.gov Identifier: NCT00002811. Available at: http://clinicaltrials.gov/ ct2/show/NCT00002811. Accessed on: March 4, 2010
51. Elmets CA et al. A phase IIb randomized, double-blind, placebo-controlled clinical trial of topical bacteriophage T4 endonuclease V in renal allograft recipients with a history of non-melanoma skin cancer. ClinicalTrials.gov Identifier: NCT00089180. Available at: http://clinicaltrials.gov/ ct2/show/NCT00089180. Accessed on: March 4, 2010
52. Fryer MJ. Evidence for the photoprotective effects of vitamin E. Photochem Photobiol. 1993;58(2):304-12.
53. Rhie G, Shin MH, Seo JY, et al. Aging- and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo. J Invest Dermatol. 2001;117(5):1212-1217.
54. Gensler HL, Magdaleno M. Topical vitamin E inhibition of immunosuppression and tumorigenesis induced by ultraviolet irradiation. Nutr Cancer. 1991;15(2):97-106.
55. Foote JA Ranger-Moore JR, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical DL-a-tocopherol. Cancer Prev Res (Phila, Pa). 2009;2(4): 394-400.
56. McCann PP, Bitonti AJ, Pegg AE. Inhibition of polyamine metabolism and the consequent effects on cell proliferation. In: L Wattenberg, ed. Cancer Chemoprevention. Boca Raton, FL: CRC Press;1992:531-539.
57. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988;48(4):759-774.
58. Pegg AE, Madhubala R, Karneji T, et al. Control of ornithine decarboxylase activity in difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues. J Biol Chem. 1988;263(22):11008-11014.
59. Elmets CA, Athar M. Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans. Cancer Prev Res (Phila, Pa). 2010;3(1):8-11.
60. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev. 2000;9(12):1281-1286.
61. Einspahr JG, Nelson MA, Saboda K, et al. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO) in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res. 2002;8(1):149-155.
62. Bailey HH, Kim K, Verma AK, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila Pa). 2010;3(1):35-47.
63. Alberts DS. Phase IIB randomized, double-blinded, placebo controlled study to evaluate the safety and efficacy of topical difluoromethylornithine (DFMO) with and without a topical corticosteroid cream (triamcinolone 0.1%) in the therapy of actinic keratoses (AK) on the forearms. ClinicalTrials.gov Identifier: NCT00021294. http://clinicaltrials.gov/ct2/show/ NCT00021294. Accessed on: March 4, 2010
64. Carbone PP. Chemoprevention of skin cancers with DFMO: a controlled, randomized clinical trial. ClinicalTrials.gov Identifier: NCT00005884. http://clinicaltrials.gov/ct2/show/ NCT00005884. Accessed on: March 4, 2010
65. Edwards L, Levine N, Weidner M, et al. Effect of intralesional interferon in actinic keratoses. Arch Derm. 1986;122:779-782.
66. Edwards L, Levine N, Smiles KA. The effect of topical interferon alpha 2b on actinic keratoses. J Dermatol Surg Oncol. 1990;16(5):446-449.
67. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol. 1999;141(3):415-423.
68. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006;54(6):1033-1038.
69. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23:694-700.
70. Chimenti S, Peris K, Di Cristofaro S, et al. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology. 1995;190:214-217.
71. Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Derm. 1986; 15:437-443.
72. Stenquist B, Wennberg AM, Gisslen H, et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Derm. 1992; 27:65-69.
73. Bostanci S, Kocyigit P, Alp A, et al. Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon alpha-2a: evaluation of long-term follow-up results. Clin Drug Investig. 2005;25(10):661-667.
74. Ikic D, Padovan I, Pipic N, et al. Interferon therapy for basal cell carcinoma and squamous cell carcinoma. Int J Clin Pharm Ther Toxicol. 1991;29:342-346.
75. Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinoma by intralesional interferon-alp 2b therapy. Arch Derm. 1992;128:1486-1489.
76. Buechner S. Intralesional interferon-alpha 2b in the treatment of basal cell carcinoma. J Am Acad Derm. 1991;24:731-734.
77. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, et al. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262.
78. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4(2):221-222.
79. Egberts F, Lischner S, Russo P, et al. Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risk for the fetus? J Dtsch Dermatol Ges. 2006;4:717-720.
80. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol. 2006;5(2):167-173.
81. Chakrabarty A, Geisse JK. Medical therapies for non-melanoma skin cancer. Clin Dermatol. 2004;22(3):183-188.
82. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica. 1979;158(5):368-372.
83. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol. 1985;121(2):207-213.
84. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114(7):1021-1022.
85. Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-fluorouracil. J Cutan Med Surg. 2003;7(2):101-105.
86. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol. 2003;148(3):539-543.
87. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156(2):320-328.
88. Hamouda B, Jamila Z, Najet R, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol. 2001;44(6):1054.
89. Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol. 2000;23(2):181-184.
90. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol. 2009;145(2):203-205.
91. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22-29.
92. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990-1000.
93. Berman B, Bienstock L, Kuritzky L, et al; Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006;55(5):suppl 1-8.
94. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol. 1991;25(4):665-667.
95. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-16.
96. Fu W, Cockerell C. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol. 2003;139(1):66-70.
97. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007;6(8):778-781.
98. The VA Keratinocyte Carcinoma Chemoprevention Trial (VAKCCT). ClinicalTrials.gov Identifier: NCT00847912. http://www.clinicaltrials.gov/ct2/show/NCT00847912. Accessed on: March 4, 2010
99. FDA Approval for Imiquimod. National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-imiquimod Accessed on: March 4, 2010
100. Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8-13.
101. Yamamoto Y, Uede K, Otani T, et al. Different apoptotic patterns observed in tissues damaged by phenol and TCA peels. J Dermatol Sci. 2006; 2(suppl):75-81.
102. Stuzin JM. Phenol peeling and the history of phenol peeling. Clin Plast Surg. 1998;25:1-19.
103. Kaminaka C, Yamamoto Y, Yonei N, et al. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol. 2009;60(4):615-625.
104. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110:734-739.
105. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999;191:10-19.
106. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
107. Clifford JL, Walch E, Yang X, et al. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002;8:2067-2072.
108. Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95(15):1138-1149.
109. Schön MP, Wienrich BG, Drewniok C, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol. 2004;122(5):1266-1276.
110. Cryns V, Yuan J. Proteases to die for. Genes Dev. 1998;12(11):1551-1570.
111. Tyring S, Conant M, Marini M, et al. Imiquimod: an international update on therapeutic uses in dermatology. Int J Dermatol. 2002;41(11):810-816.
112. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol. 2006;154(1):72-78.
113. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138(11):1498-1502.
114. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47(4):571-577.
115. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50(5):714-721.
116. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547-555.
117. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9(5):209-214.
118. Stockfleth E, Sterry W, Carey-Yard M, et al. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157 Suppl 2:41-46.
119. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157(1): 133-141.
120. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141(4):467-473.
121. Zeichner JA, Stern DW, Uliasz A, et al. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol. 2009;60(1):59-62.
122. Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11(6):195-201.
123. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157 Suppl 2:25-31.
124. Swanson N, Rosen T, Berman B, et al. Optimizing imiquimod for treating actinic keratosis of the full face or balding scalp: imiquimod 2.5% and 3.75% applied daily for two 2-week or 3-week cycles. Presented at: The 12th World Congress on Cancers of the Skin; May 3-6, 2009; Tel-Aviv, Israel.
125. Swanson N, Hanke CW, Berman B, et al. Twelve month sustained clearance of actinic keratoses of the full face or balding scalp after imiquimod 2.5% and 3.75% applied daily for two 2-week or 3-week cycles. Presented at: The Hawaii Dermatology Seminar; February 2010; Waikaloa, Hawaii.
126. Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025-1032.
127. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg. 2007;33(4):427-431.
128. Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55(2): 324-327.
129. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002;46(4):545-548.
130. Orengo I, Rosen T, Guill CK. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol. 2002;47(4 Suppl):S225-S228.
131. van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007;46(3):318-319.
132. Thai KE, Sinclair RD. Treatment of Bowen's disease of the penis with imiquimod. J Am Acad Dermatol. 2002;46(3): 470-471.
133. Taliaferro SJ, Cohen GF. Bowen's disease of the penis treated with topical imiquimod 5% cream. J Drugs Dermatol. 2008;7(5):483-485.
134. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol. 2001;137(1):14-16.
135. Brannan PA, Anderson HK, Kersten RC, et al. Bowen disease of the eyelid successfully treated with imiquimod. Ophthal Plast Reconstr Surg. 2005;21(4):321-322.
136. Kossard S. Treatment of large facial Bowen's disease: case report. Clin Exp Dermatol. 2003;28 Suppl 1:13-15.
137. Prabhu S, Rao R, Sripathi H, et al. Successful use of imiquimod 5% cream in Bowen's disease. Indian J Dermatol Venereol Leprol. 2007;73(6):423-425.
138. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27(6):561-564.
139. Murua AA, González LC, García-Río I, et al. Coexisting perianal squamous cell carcinoma, Bowen's disease, and condylomata acuminata treated with topical imiquimod 5%. Int J Dermatol. 2008;47(12):1334-1336.
140. Konstantopoulou M, Lord MG, Macfarlane AW. Treatment of invasive squamous cell carcinoma with 5-percent imiquimod cream. Dermatol Online J. 2006;12(3):10.
141. Nouri K, O'Connell C, Rivas MP. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. J Drugs Dermatol. 2003;2(6):669-673.
142. Martin-Garcia RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg. 2005;31(3):371-374.
143. Oster-Schmidt C. Two cases of squamous cell carcinoma treated with topical imiquimod 5%. J Eur Acad Dermatol Venereol. 2004;18(1):93-95.
144. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol. 2004;140:404-406.
145. Flórez Á, Feal C, de la Torre C, Cruces M. Invasive squamous cell carcinoma treated with imiquimod 5% cream. Acta Derm Venereol. 2004;84:227-228.
146. Oster-Schmidt C, Dirschka T. Therapy of cutaneous cell carcinoma in two retirement home residents. J Dtsch Dermatol. 2005;3(9):705-708.
147. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.
148. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41(6):1002-1007.
149. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390-398.
150. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939-947.
151. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9): 1165-1171.
152. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6): 1227-1236.
153. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431-1438.
154. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 1995;58:365-372.
155. Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res. 1995;28:253-264.
156. Jones T. Resiquimod 3M. Curr Opin Investig Drugs. 2003;4:214-218.
157. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205-210.
158. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833-2839.
159. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16-22.
160. Weedon D, Chick J. Home treatment of basal cell carcinoma. Med J Aust. 1976;1:928.
161. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australas J Dermatol. 1988;29:127-130.
162. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene. 2003;22:3152-3161.
163. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153-164.
164. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123-8132.
165. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934-943.
166. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (Ingenol Mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (region-IIa). ClinicalTrials.gov Identifier: NCT00916006. http://www.clinicaltrials.gov/ct2/show/NCT00916006. Accessed on: March 4, 2010.
167. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (Ingenol Mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (region-IIb). ClinicalTrials.gov Identifier: NCT00915551. http://www.clinicaltrials.gov/ct2/show/NCT00915551. Accessed on: March 4, 2010.
168. A multi-center, open-label study to evaluate the safety and efficacy of PEP005 (Ingenol Mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (trunk and extremities). ClinicalTrials.gov Identifier: NCT00917306. http://www.clinicaltrials.gov/ct2/show/NCT00917306. Accessed on: March 4, 2010.
169. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (Ingenol Mebutate) gel, 0.05%, in patients with actinic keratoses on n-head locations (region-Ib). ClinicalTrials.gov Identifier: NCT00942604. http:// www.clinicaltrials.gov/ct2/show/NCT00942604. Accessed on: March 4, 2010.
170. Marks F, Fürstenberger G, Müller-Decker K. Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res. 1999;151:45-67.
171. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30(1):3-21.
172. Kundu N, Smyth MJ, Samsel L, Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat. 2002;76(1):57-64.
173. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 2002;76(1):73-80.
174. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133(10):1239-1242.
175. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709-713.
176. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol. 1997;38(4):187-189.
177. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5(2):156-159.
178. Kose O, Koc E, Erbil AH, et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008;19(3):159-163.
179. Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment ofactinic keratoses. Skin Therapy Lett. 2004;9(1):1-3.
180. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7(7):669-673.
181. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94-100.
182. Clouser MC, Roe DJ, Foote JA, et al. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf. 2009;18(4):276-283.
183. Dawe SA, Salisbury JR, Higgins E. Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel. Clin Exp Dermatol. 2005;30(6):712-713.
184. Patel MJ, Stockfleth E. Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol. 2007;156 Suppl 3:53-56.
185. Neubert T, Lehmann P. Bowen's disease-a review of newer treatment options. Ther Clin Risk Manag. 2008;4(5): 1085-1095.
186. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev. 2004;28(2):127-142.
187. A phase II/III randomized, double-blind, placebo-controlled clinical trial of celecoxib in subjects with actinic keratoses. ClinicalTrials.gov Identifier: NCT00027976. http://clinical trials.gov/ct2/show/NCT00027976. Accessed on: March 4, 2010.
188. A phase II randomized, double-blind, placebo-controlled clinical trial of Celecoxib in subjects with basal cell nevus syndrome. ClinicalTrials.gov Identifier: NCT00023621. http://clinicaltrials.gov/ct2/show/NCT00023621. Accessed on: March 4, 2010.
189. Jäger S, Laszczyk MN, Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules. 2008;13(12): 3224-3235.
190. Krasutsky PA. Birch bark research and development. Nat Prod Rep. 2006;23(6):919-942.
191. Huyke C, Reuter J, Rödig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7(2):128-133.
192. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development. 1998;125(18): 3553-3562.
193. Miller SJ, Yu TC. Cyclopamine as a potential therapeutic agent for treatment of tumors related to hedgehog pathway mutations. Dermatol Surg. 2002;28(2):187.
194. McMahon AP. More surprises in the hedgehog signaling pathway. Cell. 2000;100(2):185-188.
195. Lupi O. Correlations between the Sonic hedgehog pathway and basal cell carcinoma. Int J Dermatol. 2007;46(11): 1113-1117.
196. Rudin CM. Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer Prev Res (Phila Pa). 2010;3(1): 1-3.
197. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
198. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668-1671.
199. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
200. Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med. 2009;361(12):1202-1205.
201. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-1178.
202. A randomized, phase II multicenter trial evaluating the efficacy and safety of a systemic hedgehog pathway antagonist (GDC-0449) in patients with basal cell nevus syndrome (BCNS). ClinicalTrials.gov Identifier: NCT00957229. http://www.clinicaltrials.gov/ct2/show/ NCT00957229. Accessed on: March 4, 2010
203. An open-label, multicenter extension study of GDC-0449 (hedgehog pathway inhibitor) in patients treated with GDC-0449 in a previous Genentech-sponsored phase I or phase II cancer study. ClinicalTrials.gov Identifier: NCT00959647. http://www.clinicaltrials.gov/ct2/show/NCT00959647. Accessed on: March 4, 2010
204. Buggiani G, Troiano M, Rossi R, et al. Photodynamic therapy: off-label and alternative use in dermatological practice. Photodiagnosis Photodyn Ther. 2008;5(2):134-138.
205. Wang XL, Wang HW, Guo MX et al. Treatment of skin cancer and pre-cancer using topical ALA-PDT-a single hospital experience. Photodiagnosis Photodyn Ther. 2008;5(2): 127-133.
206. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47(2):258-262.
207. Touma D, Yaar M, Whitehead S, Konnikov N, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140(1):33-40.
208. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125-143.
209. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140(1):41-46.
210. Apalla Z, Sotiriou E, Chovarda E, et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo controlled study. Br J Dermatol. 2010;162(1):171-175. Epub 2009 Oct 26.
211. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48(2):227-232.
212. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85(5): 424-428.
213. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14(2): 99-106.
214. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2(6):629-635.
215. Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol. 2009;23(9):1061-1065. Epub 2009 Apr 8.
216. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol. 2009;8(1):35-39.
217. de Haas ER, de Vijlder HC, Sterenborg HJ, et al. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2008;22(4): 426-430.
218. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br J Dermatol. 2009;161(1):170-173.
219. Marcus SL. A randomized, evaluator-blinded, parallel group comparison of PDT with Levulan topical solution plus blue light versus Levulan Topical Solution Vehicle plus blue light for the treatment of AK and reduction of new NMSC in organ transplant recipients. ClinicalTrials.gov Identifier: NCT00865878.http:// clinicaltrials.gov/ct2/show/NCT00865878.Accessed on: March 4, 2010.
220. Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for non-melanoma skin cancer prophylaxis. Arch Dermatol. 2006;142(8):976-982.
221. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg. 1997;23(10):885-889.
222. Massey RA, Eliezri YD. A case report of laser resurfacing as a skin cancer prophylaxis. Dermatol Surg. 1999;25(6): 513-516.
223. Iyer S, Friedli A, Bowes L, et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med. 2004;34(2): 114-119.
224. Ostertag JU, Quaedvlieg PJ, Neumann MH, et al. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg. 2006;32(2):261-267.
225. Halachmi S, Lapidoth M. Lasers in skin cancer prophylaxis. Expert Rev Anticancer Ther. 2008;8(11):1713-1717.
226. Covadonga Martínez-González M, del Pozo J, Paradela S, et al. Bowen's disease treated by carbon dioxide laser. A series of 44 patients. J Dermatolog Treat. 2008;19(5):293-299.
227. Moskalik K, Kozlov A, Demin E, et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. Photomed Laser Surg. 2009;27(2): 345-349.
228. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8): 1869-1878.
229. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754--578.
230. CT-2) A multicentre, randomised, double-blind, placebo controlled, phase II study to evaluate the safety and efficacy of subcutaneous bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients. ClinicalTrials.gov Identifier: NCT00829192. http:// www.clinicaltrials.gov/ ct2/show/NCT00829192. Accessed on: March 4, 2010.
231. Toll A, Salgado R, Yébenes M, et al. Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol. 2010;19(2):151-153.
232. Seiverling EV, Fernanadez EM, Adams D. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. J Drugs Dermatol. 2006;5(4):368-369.
233. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22;290(16): 2149-2158.
234. A phase II study of ZD1839 (Iressa), epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treatment of recurrent or metastatic squamous cell carcin- oma of the skin. ClinicalTrials.gov Identifier: NCT00054691.http://www.clinicaltrials.gov/ct2/ show/NCT00054691. Accessed on: March 4, 2010.
235. A phase III trial of Erlotinib and radiotherapy in patients with stage III cutaneous squamous cell carcinomas. ClinicalTrials.gov Identifier: NCT00369512. http://www. clinicaltrials.gov/ct2/show/NCT00369512. Accessed on: March 4, 2010.
236. Multicenter randomized phase II study of Erlotinib, Cisplatin and radiotherapy versus Cisplatin and radiotherapy in patients with stage III and IV squamous cell carcinoma of the head and neck. ClinicalTrials.gov Identifier: NCT01009489. http://www.clinicaltrials.gov/ct2/show/NCT01009489. Accessed on: March 4, 2010.
237. Randomized study of Bevacizumab/Tarceva and Tarceva/Sulindac in squamous cell carcinoma of the head and neck. ClinicalTrials.gov Identifier: NCT00392665. http://www.clinicaltrials.gov/ct2/show/NCT00392665. Accessed on: March 4, 2010.
238. Phase I/II study of secondary primary tumor prevention with epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor Erlotinib (OSI-774, Tarceva™), and cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in early stage (stage I/II) squamous cell carcinoma of head and neck. ClinicalTrials.gov Identifier: NCT00400374. http://www.clinicaltrials.gov/ct2/ show/NCT00400374. Accessed on: March 4, 2010.
239. Phase II study of Cetuximab as monotherapy and first line Treatment in patients with locally advanced or metastatic squamous cell carcinoma of the skin expressing EGFR. ClinicalTrials.gov Identifier: NCT00240682. http://www. clinicaltrials.gov/ct2/show/NCT00240682. Accessed on: March 4, 2010.
240. Phase 2, single-arm, open-label, multi-center trial of second-line panitumumab monotherapy in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. ClinicalTrials.gov Identifier: NCT00446446. http://www. clinicaltrials.gov/ct2/show/NCT00446446. Accessed on: March 4, 2010.
241. A randomized, open-label, controlled, phase II trial of combination chemotherapy with or without panitumumab as first-line treatment of subjects with metastatic or recurrent head and neck cancer, and cross-over second-line panitumumab monotherapy of subjects who fail the combination chemotherapy. ClinicalTrials.gov Identifier: NCT00454779. http://www.clinicaltrials.gov/ct2/show/ NCT00454779. Accessed on: March 4, 2010.
242. Phase I study panitumumab plus chemoradiotherapy and induction chemotherapy in patients with locally advanced squamous cell cancer of the head and neck. ClinicalTrials.gov Identifier: NCT00513383. http://www.clinicaltrials.gov/ ct2/show/NCT00513383. Accessed on: March 4, 2010.
243. A phase 2 randomized trial of radiotherapy plus panitumumab compared to chemoradiotherapy with unresected, locally advanced squamous cell carcinoma of the head and neck. ClinicalTrials.gov Identifier: NCT00547157. http://www.clinicaltrials.gov/ct2/show/ NCT00547157. Accessed on: March 4, 2010.
244. A phase II trial of postoperative radiation, cisplatin, and panitumumab in locally advanced head and neck cancer. ClinicalTrials.gov Identifier: NCT00798655. http://www.clinicaltrials.gov/ct2/show/NCT00798655. Accessed on: March 4, 2010.
245. Jirakulaporn T, Mathew J, Lindgren BR, et al. Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol. 2009;27(15S):1519